ResMed (ASX:RMD) has secured Red Dot designation for a nasal pillow mask and a soon-to-be-launched life support ventilator at this year's awards. [ + ]

Merck Millipore, the life science division of Merck, has announced the appointment of Dr Udit Batra as its incoming president and CEO. Dr Batra comes to Merck Millipore from the consumer health division of Merck KGaA, where he successfully grew the business in established and emerging markets. [ + ]

Researchers from the University of Zurich and ETH Zurich have discovered a piece in the puzzle which explains how the inheritance of traumas may be mediated. [ + ]

The US FDA has set a PDUFA date of 26 September for pSivida (ASX:PVA) partner Alimera Sciences' fourth new drug application for diabetic macular edema treatment Iluvien.

This year's Agricultural Biotechnology International Conference (ABIC) has launched its program. Registrations are now open for the event, to be held from 5-8 October in Saskatoon, Saskatchewan, Canada. [ + ]

A leading British scientist, Professor Sir Philip Cohen FAA FRS FRSE, has been announced as a Corresponding Member of the Australian Academy of Science. [ + ]

A delegation of seven professors from Australian universities recently travelled to China to promote joint research in the musculoskeletal disciplines. [ + ]

Qiagen has acquired an exclusive worldwide licence to the biomarker calreticulin (CALR), whose mutations are found in an estimated 15% of cases of myeloproliferative neoplasms (MPNs) - a group of blood disorders involving overproduction of blood cells. [ + ]

UQ spinoff Spinifex has raised $47.7m in series C investment funding to help accelerate the clinical development of neuropathic and inflammatory pain drug EMA401. [ + ]

Olympus Australia has moved its operational headquarters to a state-of-the-art facility in Melbourne that incorporates a fully operational customer experience centre, comprehensive training facilities and the company's national service centre. [ + ]

Australian biotech company Spinifex Pharmaceuticals has attracted $48 million in funding to advance its drug for chronic pain, EMA401. The deal represents one of Australia's largest off-market investments in a private biotechnology company. [ + ]

Wild rainbowfish are more courageous than those raised in captivity, according to a study. [ + ]

AstraZeneca has arranged to evaluate using Starpharma's DEP dendrimer drug delivery technology for a second cancer drug. [ + ]

Insights into how platelet production is managed in the blood have been reported. [ + ]

Three biomedical animations that have been a year in the making are having their debut on screen. [ + ]